Wedbush reiterates Outperform on Aktis Oncology, $35 price target
Wedbush reiterated an Outperform rating on Aktis Oncology's stock with a price target of $35.00, implying an upside of 89.0% from the Oct 1 close of $18.52.
Wedbush reiterated an Outperform rating on Aktis Oncology's stock with a price target of $35.00, implying an upside of 89.0% from the Oct 1 close of $18.52.